Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study | Zendy

Kimball A.B. | Zendy; Papp K.A. | Zendy; Wasfi Y. | Zendy; Chan D. | Zendy; Bissonnette R. | Zendy; Sofen H. | Zendy; Yeilding N. | Zendy; Li S. | Zendy; Szapary P. | Zendy; Gordon K.B. | Zendy

Premium

Long‐term efficacy of ustekinumab in patients with moderate‐to‐severe psoriasis treated for up to 5 years in the PHOENIX 1 study

Author(s) -

Kimball A.B.,

Papp K.A.,

Wasfi Y.,

Chan D.,

Bissonnette R.,

Sofen H.,

Yeilding N.,

Li S.,

Szapary P.,

Gordon K.B.

Publication year - 2013

Publication title -

journal of the european academy of dermatology and venereology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.655

H-Index - 107

eISSN - 1468-3083

pISSN - 0926-9959

DOI - 10.1111/jdv.12046

Subject(s) - medicine , ustekinumab , psoriasis area and severity index , adverse effect , psoriasis , placebo , population , randomized controlled trial , clinical trial , dermatology , disease , adalimumab , alternative medicine , environmental health , pathology

Background Ongoing evaluation of biological agents in patients with moderate‐to‐severe psoriasis is needed to support their long‐term use. Objective To evaluate long‐term efficacy and safety of ustekinumab through 5 years in the PHOENIX 1 study. Methods Patients were randomized to placebo or ustekinumab (45 mg or 90 mg) at Weeks 0, 4 and every‐12‐weeks thereafter; placebo patients crossed‐over to ustekinumab at Week 12. Clinical response through Week 244 was evaluated using the Psoriasis Area and Severity Index (PASI) in the Overall Population (i.e. patients receiving ≥1 dose of ustekinumab), Initial Responders (i.e. PASI 75 responders [Weeks 28/40] re‐randomized at Week 40 to continue every‐12‐week maintenance) and Partial Responders (i.e.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research